The biotechnology company announces the issuance of a patent for its anti-Staphylococcus aureus solution.
–
–
Pherecydes Pharma obtains its first patent in China | Photo credits: Vifor Pharma
New patent for Pherecydes Pharma. The biotechnology company, which specializes in precision phage therapy for treating resistant bacterial infections, has been granted a patent in China for its anti-Staphylococcus aureus phages (viruses that only affect bacteria).
Guy-Charles Fanneau de La Horie, Chairman of the Management Board of Pherecydes Pharma, is very enthusiastic about this new patent: “ We are very happy to continue to strengthen our intellectual property by adding a territory as important as China to the phage protection universe. “. He also recalls that he ” This is the second patent issued in a few weeks for our anti-Staphylococcus aureus phages, which completes the arsenal of protection for our phage portfolio under development. ”, The first having issued by the Israeli authorities.
The company’s active portfolio now contains four patents. Pherecydes Pharma hopes to strengthen it soon, authorizations being currently under examination in certain jurisdictions, indicates the group in its press release.
The share price climbed 1.85% this Thursday morning, to 7.039 euros.
–
L.A
–
